Evidence map›Paper›PMID 38956476›Full record

ArticleBMC infectious diseases2024

Reduction in ACE2 expression in peripheral blood mononuclear cells during COVID-19 - implications for post COVID-19 conditions.

Gulrayz Ahmed, Yasir Abdelgadir, Amro Abdelghani, Pippa Simpson, Jody Barbeau, Donald Basel, Christy S Barrios, Brandon A Smith, Kala F Schilter, Rupa Udani and 2 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gulrayz AhmedMedical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID http://orcid.org/0000-0001-6873-9571
Yasir AbdelgadirMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Amro AbdelghaniMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Pippa SimpsonMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jody BarbeauMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Donald BaselMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Christy S BarriosMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Brandon A SmithMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Kala F SchilterMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Rupa UdaniMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Honey V ReddiMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Rodney E WilloughbyMedical College of Wisconsin, Milwaukee, Wisconsin, USA. rewillou@mcw.edu.ORCID http://orcid.org/0000-0001-8966-8258

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere COVID-19 is uncommon, restricted to 19% of the total population. In response to the first virus wave (alpha variant of SARS-CoV-2), we investigated whether a biomarker indicated severity of disease and, in particular, if variable expression of angiotensin converting enzyme 2 (ACE2) in blood might clarify this difference in risk and of post COVID -19 conditions (PCC).

methodsThe IRB-approved study compared patients hospitalized with severe COVID-19 to healthy controls. Severe infection was defined requiring oxygen or increased oxygen need from baseline at admission with positive COVID-19 PCR. A single blood sample was obtained from patients within a day of admission. ACE2 RNA expression in blood cells was measured by an RT-PCR assay. Plasma ACE1 and ACE2 enzyme activities were quantified by fluorescent peptides. Plasma TIMP-1, PIIINP and MMP-9 antigens were quantified by ELISA. Data were entered into REDCap and analyzed using STATA v 14 and GraphPad Prism v 10.

resultsForty-eight patients and 72 healthy controls were recruited during the pandemic. ACE2 RNA expression in peripheral blood mononuclear cells (PBMC) was rarely detected acutely during severe COVID-19 but common in controls (OR for undetected ACE2: 12.4 [95% CI: 2.62-76.1]). ACE2 RNA expression in PBMC did not determine plasma ACE1 and ACE2 activity, suggesting alternative cell-signaling pathways. Markers of fibrosis (TIMP-1 and PIIINP) and vasculopathy (MMP-9) were additionally elevated. ACE2 RNA expression during severe COVID-19 often responded within hours to convalescent plasma. Analogous to oncogenesis, we speculate that potent, persistent, cryptic processes following COVID-19 (the renin-angiotensin system (RAS), fibrosis and vasculopathy) initiate or promote post-COVID-19 conditions (PCC) in susceptible individuals.

conclusionsThis work elucidates biological and temporal plausibility for ACE2, TIMP1, PIIINP and MMP-9 in the pathogenesis of PCC. Intersection of these independent systems is uncommon and may in part explain the rarity of PCC.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19Leukocytes, MononuclearSARS-CoV-2AdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMatrix Metalloproteinase 9Middle AgedPeptidyl-Dipeptidase ASeverity of Illness IndexTissue Inhibitor of Metalloproteinase-1ACE2 protein, humanAngiotensin-Converting Enzyme 2BiomarkersMatrix Metalloproteinase 9Peptidyl-Dipeptidase ATissue Inhibitor of Metalloproteinase-1Angiotensin-converting enzyme 2; TranscriptionCOVID-19GeneticLeukocytesMatrix metalloprotease-9Mononuclear; BiomarkersN-terminal peptide of procollagen IIIPost-acute COVID-19 syndromeTissue inhibitor of metalloprotease-1

Identifiers

PMID38956476
PMCPMC11221185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.